Patents by Inventor Gary R. Ostroff
Gary R. Ostroff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020143174Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: ApplicationFiled: March 7, 2002Publication date: October 3, 2002Applicant: Biopolymer Engineering, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Gary R. Ostroff
-
Patent number: 6369216Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: June 3, 1999Date of Patent: April 9, 2002Assignee: Biopolymer Engineering Pharmaceutical, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Publication number: 20020032170Abstract: The present invention relates to neutral, aqueous soluble &bgr;-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel &bgr;-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble &bgr;-glucan preparation has a high affinity for the &bgr;-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble &bgr;-glucan of this invention neither induces nor primes IL-1&bgr;, and TNF&agr; production in vitro and in vivo.Type: ApplicationFiled: April 24, 2001Publication date: March 14, 2002Inventors: Spiros Jamas, D. Davidson Easson, Gary R. Ostroff
-
Patent number: 6022703Abstract: A cloning vector contains a DNA sequence derived from a Nocardioform microorganism, and is capable of expressing the DNA sequence in a host microorganism. Recombinant cholesterol oxidase is produced by a host microbial cell transformed with a cloning vector containing cholesterol oxidase encoding DNA derived from a Nocardioform microorganism. A method for determining cholesterol oxidase in a sample of fluid from a human includes contacting the sample with the Nocardioform microorganism derived recombinant cholesterol oxidase.Type: GrantFiled: June 21, 1993Date of Patent: February 8, 2000Assignee: Genzyme CorporationInventors: Susan Long, Gary R. Ostroff
-
Patent number: 5849720Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 1995Date of Patent: December 15, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5817643Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5811542Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: May 2, 1995Date of Patent: September 22, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5783569Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucans receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucans of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.Type: GrantFiled: January 26, 1995Date of Patent: July 21, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5741495Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: February 27, 1997Date of Patent: April 21, 1998Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
-
Patent number: 5663324Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: June 5, 1995Date of Patent: September 2, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros James, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5633369Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: June 5, 1995Date of Patent: May 27, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5622939Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g.Type: GrantFiled: August 21, 1992Date of Patent: April 22, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5622940Abstract: Methods of treating or preventing infection-induced oral tissue destruction or gingivitis in a mammal, comprising administering a therapeutically effective amount of a .beta.(1,3)-glucan, such as poly-.beta.(1-6)-glucotriosyl-.beta.(1-3)-glucopyranose glucan (PGG-glucan), are disclosed.Type: GrantFiled: July 14, 1994Date of Patent: April 22, 1997Assignee: Alpha-Beta TechnologyInventor: Gary R. Ostroff
-
Patent number: 5607677Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: December 13, 1991Date of Patent: March 4, 1997Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
-
Patent number: 5532223Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.Type: GrantFiled: May 30, 1995Date of Patent: July 2, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5504079Abstract: Modified yeast cell wall glucans are administered to patients who are at risk for infection due to imminent surgery, chemotherapy or other treatment which affects the immune system, in order to mobilize the cellular defense mechanisms and boost the immune response of the patient before, during and after the surgery, chemotherapy or other treatment.Type: GrantFiled: November 14, 1994Date of Patent: April 2, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5488040Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human mono-cytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.Type: GrantFiled: May 11, 1993Date of Patent: January 30, 1996Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5322841Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence or acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.Type: GrantFiled: November 2, 1992Date of Patent: June 21, 1994Assignee: Alpha-Beta Technology, Inc.Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 5032401Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.Type: GrantFiled: June 15, 1989Date of Patent: July 16, 1991Assignee: Alpha Beta TechnologyInventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
-
Patent number: 4595660Abstract: A mutant of Bacillus subtilis has been isolated which greatly facilitates gene cloning in this nonpathogenic microorganism. B. subtilis is a known protein secretor and can be used efficiently in commercial operations. Unlike the more commonly used clone-propagating organism E. coli., B. subtilis has the advantage of lacking pyrogenic substances in its cell envelope. However, chimeric plasmids for infection of B. subtilis have been difficult to prepare, and if E. Coli is used as an intermediate host to provide plasmid forms suitable for Bacillus transformation, the B. subtilis treats any E. coli-propagated DNA as foreign and preferentially attacks the insert portion of the plasmid. This attach results in loss of cloned genes and limits the use of B. subtilis as a cloning system. The B. subtilis recipient strain of this invention is, on the other hand, stably and efficiently transformed by E. coli-propagated plasmid DNA at high frequency.Type: GrantFiled: March 2, 1983Date of Patent: June 17, 1986Assignee: University of DelawareInventors: Gary R. Ostroff, Jacques J. Pene